ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Politics, Short Tempers, Grievances Dominate NIH Panel On Unconventional Medical Practices

September 25, 1992

In Brief: WHI Revises Protocol After Study Finds High Rate Of Endometrial Hyperplasia

January 27, 1995

Breast cancer session was ASCO equivalent of a rock concert, discussant says.

May 27, 2005

Chemotherapy After Surgery Extends Survival By 32%

January 27, 2006

NCAB Asks Speedup Of OSP Coordinating Center Review

October 14, 1983

NCI Advisors Approve $100M Set Aside for Physical Sciences-Oncology Centers.

December 12, 2008